Drug Search Results
More Filters [+]

HT-102

Alternative Names: HT-102, HT 102, HT102, BM-012, BM 012, BM012
Latest Update: None
Latest Update Note: None

Product Description

Mechanisms of Action: HBsAg Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Suzhou Boomingsai Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HT-102

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hepatitis B, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20231499

P1

Not yet recruiting

Hepatitis B, Chronic

None

Recent News Events

Date

Type

Title